Peter Wrighton-Smith, PhD

Chief Executive Officer

Dr. Wrighton-Smith started Oxford Immunotec after having spent 5 years at PowderJect Pharmaceuticals PLC, now part of Chiron Corporation. During his time there, he saw PowderJect grow to a global vaccines business with over 1,000 employees and immediately prior to founding Oxford Immunotec, he was Special Projects Director at PowderJect. Prior to that, he was Managing Director of PowderJect Diagnostics Ltd, a subsidiary of PowderJect, developing cellular immune based diagnostics. He has also held scientific, business development & project management roles at major companies in both the healthcare and engineering fields, including posts in Switzerland and California. Peter has a Masters in Engineering, Economics & Management, and a DPhil in Medical Engineering both from Oxford University.

Back to top

Peter Edwardson, PhD

Chief Scientific Officer 

Dr. Edwardson has over 20 years experience in the medical device industry in both small start-up companies and large corporations. Most recently, Peter was VP of Medical Technologies, Prometic Biosciences Ltd., where he led a joint venture with the American Red Cross to develop products to remove pathogens from blood. Prior to this, he was Technical Director at Tayside Flow Technologies and Tissuemed Ltd, start-up companies focused on development and commercialization of implantable devices. Peter is author of numerous scientific publications and international patents and has a PhD from Cambridge University.

Back to top

Jeff Schroeder

President, North America 

Mr. Schroeder has over 20 years experience in the diagnostics business. Prior to joining Oxford Immunotec, he served as Vice-President of Marketing at Cytyc Corporation where he led the product marketing team to develop and execute the strategic plan for the ThinPrep Pap Test and ThinPrep Imaging System. Subsequently at Cytyc he ran a newly-acquired sales team to achieve sales targets for the MammoSite Radiation Therapy System, a device for breast cancer radiation therapy used by breast surgeons and radiation oncologists. Prior to Cytyc, he managed sales, marketing and customer service for CytoLogix Corporation, a venture funded cellular diagnostics company in Cambridge, Massachusetts. Jeff previously spent 16 years in sales and marketing positions in medical diagnostics at Abbott Laboratories.

Back to top

Simon Turner

Vice President, Finance and Administration 

Mr. Turner joined Oxford Immunotec after having spent six years in major merchant banks, including JP Morgan and Deutsche Bank where he was responsible for trading programs in fixed income, metals and derivatives sectors.  Most recently he was VP Strategic Initiatives for Bank of America.  Simon originally trained in chemical engineering, before joining the accountancy firm Binder Hamlyn where he qualified as an accountant before entering the banking industry.  Simon is a Chartered Accountant and has a Masters in Finance from London Business School.

Back to top

Jon Watts

Vice President, Business Development 

Mr. Watts has more than 25 years' experience in sales, marketing and business development in the pharmaceutical, diagnostic and biotechnology sectors. During his career in the industry Jon served in increasingly senior positions with Astra, Becton Dickinson and RP Scherer and was Director of Business Development at Cortecs Plc prior to joining PowderJect Plc where he served as VP of Business Development. He founded Medborough Ltd a business development consultancy in 2003 whose client list includes major corporations, biotech start ups and marketing companies. Jon joined Oxford Immunotec in February 2007.

Back to top

Frank Vandeputte

Vice President, Sales and Marketing

With over 20 years experience in the medical devices industry, Mr. Vandeputte has held senior management positions with leading companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation. The former VP, Europe for CryoCath Technologies Inc. (TSX:CYT), Mr. Vandeputte headed the European business operation, responsible for developing and implementing strategic and operational business plans with the objective of driving rapid sales growth for cryotherapy products in the European market. Prior to CryoCath, he served as VP, International Marketing and subsequently Area VP, Benelux and Nordic for the Sorin Group.

Back to top

Patricia Randall

Vice President and General Counsel 

Ms. Randall has more than thirty years experience as a lawyer and advisor to both public and private companies in a wide range of industries. Most recently, she served as vice president, general counsel and secretary of Matritech, Inc. (AMEX:MZT), a biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers. Previously, she served as vice president and general counsel of Hadco Corporation (NYSE:HDC), a global manufacturer of printed circuit boards, and as vice president and general counsel of Robotic Vision Systems, Inc. (NASD: ROBV), a leading supplier of machine vision technologies. Pat also serves on the board of directors of Belmont Instrument Corporation, a private medical device company.

Back to top